Carcinogenesis Advance Access published online on March 2, 2006
Carcinogenesis, doi:10.1093/carcin/bgl001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Community, Occupational and Family Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
* To whom correspondence should be addressed. Peroxisome proliferator-activated receptor (PPAR)
Received November 23, 2005
Revised January 31, 2006
Accepted February 21, 2006
MOLECULAR EPIDEMIOLOGY AND CANCER PREVENTION
Peroxisome proliferator-activated receptor (PPAR)
Woon-Puay Koh 1 *,
Jian-Min Yuan 2,
David Van Den Berg 3,
Sue A. Ingles 3,
and
Mimi C. Yu 2
gene polymorphisms and colorectal cancer risk among Chinese in Singapore
2 The Cancer Center, University of Minnesota, Minneapolis, USA
3 USC/Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
Woon-Puay Koh, E-mail: cofkwp{at}nus.edu.sg
![]()
Abstract
is a ligand-activated nuclear receptor that plays a key role in adipogenesis and adipocyte gene expression, and has recently been linked with possible antineoplastic effects in colonic carcinogenesis. PPAR
2 and PPAR
3 are two transcripts arising from the PPAR
gene through differential promoter usage and alternative splicing. We investigated the associations between PPAR
2 Pro12Ala and PPAR
3 C-681G gene polymorphisms and colorectal cancer risk in a case-control study nested within the Singapore Chinese Health Study. Genotypes for the PPAR
2 and PPAR
3 polymorphisms were determined on 362 incident colorectal cancer cases and 1164 cohort controls by direct sequencing and by fluorogenic 5'-nuclease assay. Unconditional logistic regression models were used for statistical analyses. With adjustment for colorectal cancer risk factors, subjects with one or two copies of the G allele of the PPAR
2 Pro12Ala polymorphism showed a statistically significant reduction in risk compared to those with the CC genotype [odds ratio (OR) = 0.53, 95% confidence interval (CI) = 0.30-0.92]. For the PPAR
3 C-681G polymorphism, subjects with one or two copies of the C allele showed a reduction in risk compared to those with the GG genotype (OR = 0.72, 95% CI = 0.51-1.04). When PPAR
2 and PPAR
3 genotypes were considered simultaneously, the number of putative low-risk genotypes was significantly associated with reduced risk of colorectal cancer in a gene-dose dependent manner; the OR (95% CI) was 0.72 (0.49-1.07) among subjects possessing one low-risk genotype (either PPAR
2 or PPAR
3), and the comparable figure among subjects possessing both low-risk genotypes was 0.19 (0.07-0.51).
; colorectal cancer; gene polymorphism.
![]()
CiteULike
Connotea
Del.icio.us What's this?